- In January 2025, Bayer AG and its wholly owned subsidiary, BlueRock Therapeutics LP, revealed plans to launch a Phase III clinical trial for bemdaneprocel, an investigational cell therapy for Parkinson’s disease. The registrational trial, called exPDite-2, is set to begin in the first half of 2025 and will mark a significant milestone in the advancement of allogeneic cell-based therapies for neurodegenerative diseases
- In January 2025, Johnson & Johnson and Intra-Cellular Therapies, Inc. announced a definitive agreement in which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies, a biopharmaceutical company specializing in the development and commercialization of therapeutics for central nervous system (CNS) disorders
- In October 2024, Novartis announced that the US Food and Drug Administration (FDA) granted accelerated approval for Scemblix (asciminib) to treat adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP). This accelerated approval is based on the major molecular response rate (MMR) at week 48 from the ASC4FIRST Phase III trial, which compared once-daily Scemblix to other investigator-selected standard of care (SoC) tyrosine kinase inhibitors
- In February 2024, Roche Pharma India unveiled its groundbreaking drug, Ocrevus (Ocrelizumab), for the treatment of multiple sclerosis (MS). Most people are diagnosed with MS between the ages of 20 and 40, making it a leading cause of non-traumatic disability in younger adults. Ocrevus is the only monoclonal antibody approved for treating both relapsing-remitting MS (RRMS) and primary progressive MS (PPMS)
- In March 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET (zavegepant), the first and only nasal spray calcitonin gene-related peptide (CGRP) receptor antagonist for the acute treatment of migraine, with or without aura, in adults. In its pivotal Phase 3 study, ZAVZPRET demonstrated statistically superior results compared to placebo on the co-primary endpoints
